


Droplet Digital™ PCR: Multiplex Detection of *KRAS* Mutations in Formalin-Fixed, Paraffin-Embedded Colorectal Cancer Samples

Wei Yang, Dawne N Shelton, Jennifer R Berman, Bin Zhang, Samantha Cooper, Svilen Tzonev, Eli Hefner, and John F Regan
Digital Biology Center, Bio-Rad Laboratories, Inc., 5731 W Las Positas Blvd, Pleasanton, CA 94588



Droplet Digital PCR

Bulletin 6578

Abstract

Targeted therapies in many cancers have allowed unprecedented progress in the treatment of disease. However, routine implementation of genomic testing is constrained due to: 1) limited amounts of sample (pg–ng range) per biological specimen, 2) diagnostic turnaround time and workflow, 3) cost, and 4) difficulties in detection of mutational loads below 5%. *KRAS* is mutated in approximately 40% of colorectal cancers (CRCs). The majority of mutations affect codons 12, 13, and 61 and indicate a negative response to anti-epidermal growth factor receptor (EGFR) therapy. To optimize therapy strategies for personalized care, it is critical to rapidly screen patient samples for the presence of multiple *KRAS* mutations.

We have developed a multiplexing strategy to screen seven actionable *KRAS* mutations in colorectal cancer samples using digital PCR. This panel includes *KRAS* point mutations with individual frequencies higher than 1% and covers 98% of *KRAS* mutant colorectal cancers (Faulkner et al. 2010, unpublished data). No preamplification step is required. This *KRAS* screening assay was used to quantify *KRAS* mutational load in a panel of formalin-fixed, paraffin-embedded (FFPE) samples from patients with advanced metastatic colorectal cancer. *KRAS* mutations present at <1% fractional abundance were detected in multiple samples. This sensitive and inexpensive method reduces the risk of contamination and can be easily implemented for rapid, routine screening of cancer samples.

Materials and Methods

- 16 mCRC (7 female, 9 male, average age 64 years) and 4 grossly normal colon (2 female, 2 male, average age 65 years) FFPE blocks were purchased (Advanced Tissue Services). mCRC samples were classified as *KRAS* mutation positive by the vendor. Samples were prepared using standard protocols (QIAGEN)
- Droplet Digital PCR (ddPCR™) was performed on 1–5 µl per sample per well using either a multiplexed *KRAS* G12/G13 Assay or validated PrimePCR™ ddPCR Mutation Assay for one of seven individual *KRAS* mutations (G12D, G12V, G13D, G12A, G12C, G12R, G12S, Bio-Rad)
- Positive mutation references were from Horizon Diagnostics, and negative controls were wild-type—only from Promega Corporation (female genomic DNA [gDNA]). Statistical significance was determined using 95% confidence intervals

Results are shown in Figures 1–4.




Fig. 1. Multiplexed single-well detection of seven actionable KRAS mutations. A, 2-D scatter plot; **B**, fractional abundance dilution series data.




Fig. 2. FFPE samples yield low and variable amounts of amplifiable DNA. Duplexed reference assays (*AP3B1*, *EIF2C1*) were used to estimate the fraction of sample that could be PCR amplified. Eleven of 16 mCRC samples had <5% amplifiable material (**A**). Sensitivity is a function of percentage mutant (x-axis) and total amplifiable copies screened (y-axis). At least 5 ng of amplifiable DNA (~1,500 copies) per sample is required to reliably detect mutations present at 0.2% (**B**). 2-D scatter plots allow visualization and troubleshooting of PCR inhibition. For sample F7K, 20% of material is amplifiable, but the inhibitors present (5 μ l loading) impact positive amplitudes (**C**). Loading less of sample F7K (2 μ l) allows better amplification (**D**).




Fig. 3. Detection and quantification of KRAS mutations. Quantification of KRAS mutational load across 16 mCRC FFPE samples was determined by a multiplex screening assay. Six samples had a mutation fractional abundance of <3%. Seven individual KRAS mutation assays were used to identify the dominant or sole KRAS mutation picked up by the initial screen (A). Consistent with the catalogue of somatic mutations in cancer (COSMIC) database, the majority of KRAS mutations (>80%) in these mCRC samples contained either G12D, G12V, G13D, or G12S (B). Quantification of KRAS mutational load by either a multiplex screening assay (y-axis) or individual mutation assay duplexes (x-axis) is tightly correlated (C). Two examples illustrate how KRAS mutational burden can be attributed to a single mutation (G12D, sample F3K) (D), or to more than one mutation (G12D plus G12S, sample M6K) (E). Inc, inconclusive.




Fig. 4. Pretreatment of FFPE sample with uracil DNA glycosylase (UDG) prevents false-positive signal. Treatment of DNA with formalin causes multiple forms of DNA damage. Treatment with UDG digests deaminated cytosines, removing cytosine>thymine (C>T) false positives. When pretreated with UDG, an FFPE sample (M2W, grossly normal) showed significantly lower G13D mutant positive droplets (A and B, events 12 vs. 2, respectively), altering the sample call from mutant to wild type. The fractional abundance of G13D mutants in the control (no treatment) compared to the sample with UDG is significantly different, indicating that the UDG treatment may result in a different call (C).

Conclusions

- We have demonstrated sensitive and precise detection (less than 1%, single reaction) of multiple actionable KRAS mutations in FFPE samples from patients with colorectal cancer
- Concordance between duplex- and multiplex-based detection is excellent
- Droplet Digital PCR provides a simple and robust workflow for mutation detection of patient samples in a rapid and cost-effective manner
- UDG treatment of FFPE DNA reduces the false positives generated by deaminated C>T transitions caused by formalin fixation

References

Do H and Dobrovic A (2012). Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. *Oncotarget* 3, 546–558.

Faulkner NE et al. KRAS mutation analyses of more than 16,500 colorectal carcinomas. Poster presented at: 2010 ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer; October 18–20, 2010; Hollywood, Florida [unpublished data].

Visit bio-rad.com/web/ddPCRKRAS for more information.

FAM is a trademark of Applied Biosystems Corporation.



**Bio-Rad
Laboratories, Inc.**

Life Science
Group

Web site www.bio-rad.com **USA** 800 424 6723 **Australia** 61 2 9914 2800 **Austria** 01 877 89 01 **Belgium** 09 385 55 11 **Brazil** 55 11 3065 7550
Canada 905 364 3435 **China** 86 21 6169 8500 **Czech Republic** 420 241 430 532 **Denmark** 44 52 10 00 **Finland** 09 804 22 00
France 01 47 95 69 65 **Germany** 089 31 884 0 **Greece** 30 210 9532 220 **Hong Kong** 852 2789 3300 **Hungary** 36 1 459 6100 **India** 91 124 4029300
Israel 03 963 6050 **Italy** 39 02 216091 **Japan** 81 3 6361 7000 **Korea** 82 2 3473 4460 **Mexico** 52 555 488 7670 **The Netherlands** 0318 540666
New Zealand 64 9 415 2280 **Norway** 23 38 41 30 **Poland** 48 22 331 99 99 **Portugal** 351 21 472 7700 **Russia** 7 495 721 14 04
Singapore 65 6415 3188 **South Africa** 27 861 246 723 **Spain** 34 91 590 5200 **Sweden** 08 555 12700 **Switzerland** 026 674 55 05
Taiwan 886 2 2578 7189 **Thailand** 1800 88 22 88 **United Kingdom** 020 8328 2000